Brind.

cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.

1 report, 1 independent Updated Jun 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

HUMIRA Blackstone Bristol-Myers Squibb

Keep exploring

The entities involved

HUMIRA
Czech company
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
- Lost patent protection for Humira in the US on August 20, 2025.Thu 06:13
Blackstone
town in Worcester County, Massachusetts, United States
- Blackstone and British Columbia Investment Management Corporation are investing in Aeroplan to support Air Canada's growth strategy.Mon 13:19
- Fact-checking reveals that shared business ties connect founders of companies like Collins and Blackstone to current political donors, including those linked to Jeffrey Epstein.Sat 07:00
Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09

Coverage

Newest first; wire copies grouped

Jun 18biopharmadive.com